Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its ...

Research reveals groundbreaking results about Mounjaro and Ozempic in weight loss treatment. Here's what you need to know ...

Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for ...

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

Incretins such as glucagon-like peptide-1, or GLP-1, are used in diabetes and obesity drugs like Eli Lilly's Mounjaro and Zepbound. The stock (LLY) dropped 8.2% in morning trading, enough to make it ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.

The company expects Q4 2024 revenue of approximately $13.5 billion. The updated revenue guidance is $400 million lower than ...

The company's shares were trading at $740.80, on track for their worst single-day decline in nearly four years. Lilly's stock ...

Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street ...

Eli Lilly blamed the shortfall on lower-than-anticipated demand for its weight-loss drugs. Indeed, the drug maker estimated ...

Retatrutide, an experimental drug by Eli Lilly, shows promising results in weight loss by targeting three hormones, ...